Teva v. Eli Lilly: Teva Argues Lilly Is Infringing Migraine Drug Patent in the United States
2 Pages Posted: 21 Aug 2018
Date Written: December 1, 2017
This complaint constitutes the last stage of a race involving several pharmaceutical companies competing to develop new products to treat migraines. Given the scarce availability of preventive therapeutic options, the market potential for innovative calcitonin gene-related peptide based drugs for the treatment of migraine – such as Fremanezumab and Galcanezumab – is particularly relevant, estimated around $8 billion to $10 billion.
Keywords: Pharmaceutical; Intellectual Property; Patents; Patent Infringement.
Suggested Citation: Suggested Citation